University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 4P-19-5


A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (MK-3475-921) (KEYNOTE-921)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Aaron Mejia, D.M., Cheryl Kefauver, Coordinator, Monica Flores, D.M., Gregory Samuel, Coordinator, Lagrimas Ilagan, D.M., Mary Ordaz, D.M., Roberto Tejada, Coordinator, Kristy Sartor Massopust, Coordinator, Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Amanda Luna, Coordinator, Niranjan Bhatt, D.M., Meena Ibrahim, D.M., Bartolo Santos, Coordinator, Aubrianne Cho, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.